Recent Analysts’ Ratings Updates for Replimune Group (REPL)

Several brokerages have updated their recommendations and price targets on shares of Replimune Group (NASDAQ: REPL) in the last few weeks:

• 7/2/2026 – Replimune Group was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 6/30/2026 – Replimune Group was upgraded by BMO Capital Markets from “underperform” to “outperform”. They now have a $16.00 price target on the stock.
• 6/30/2026 – Replimune Group had its price target raised by Wedbush from $6.00 to $9.00. They now have a “neutral” rating on the stock.
• 6/26/2026 – Replimune Group was upgraded by JPMorgan Chase & Co. from “neutral” to “overweight”. They now have a $17.00 price target on the stock.
• 6/18/2026 – Replimune Group was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 6/3/2026 – Replimune Group was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 6/1/2026 – Replimune Group had its price target raised by Wedbush from $2.00 to $6.00. They now have a “neutral” rating on the stock.
• 5/29/2026 – Replimune Group was upgraded by JPMorgan Chase & Co. from “underweight” to “neutral”. They now have a $8.00 price target on the stock.
• 5/23/2026 – Replimune Group was upgraded by Wall Street Zen from “strong sell” to “sell”.

Insiders Place Their Bets

In other news, insider Christopher Sarchi sold 12,000 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $9.24, for a total value of $110,880.00. Following the sale, the insider owned 180,962 shares in the company, valued at approximately $1,672,088.88. This represents a 6.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is currently owned by company insiders.

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.